886979-78-8

Basic information

• Product Name: 2-PyrazinecarboxaMide, N-[(1S)-2-[[(1R)-1-hydroperoxy-3-Methylbutyl]aMino]-2-oxo-1-(phenylMethyl)ethyl]-
• Synonyms: 2-PyrazinecarboxaMide, N-[(1S)-2-[[(1R)-1-hydroperoxy-3-Methylbutyl]aMino]-2-oxo-1-(phenylMethyl)ethyl]-;N-((S)-1-(((R)-1-hydroperoxy-3-Methylbutyl)aMino)-1-oxo-3-phenylpropan-2-yl)pyrazine-2-carboxaMide;Bortezomib Impurity 12;(R)-Hydroperoxy Des(boric Acid) Bortezomib;Bortezomib Impurity 46;Bortezomib USP Related Compoud L
• CAS NO: 886979-78-8
• Molecular Formula: C19H24N4O4
• Molecular Weight: 372.41826
• EINECS: -0
• Mol File: 886979-78-8.mol
• Article Data: 0

Chemical Properties

• Appearance: /
• Storage Temp.: -20°C Freezer
• Solubility: DMSO (Slightly), Methanol (Slightly, Heated)
• CAS DataBase Reference: 2-PyrazinecarboxaMide, N-[(1S)-2-[[(1R)-1-hydroperoxy-3-Methylbutyl]aMino]-2-oxo-1-(phenylMethyl)ethyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: 2-PyrazinecarboxaMide, N-[(1S)-2-[[(1R)-1-hydroperoxy-3-Methylbutyl]aMino]-2-oxo-1-(phenylMethyl)ethyl]-(886979-78-8)
• EPA Substance Registry System: 2-PyrazinecarboxaMide, N-[(1S)-2-[[(1R)-1-hydroperoxy-3-Methylbutyl]aMino]-2-oxo-1-(phenylMethyl)ethyl]-(886979-78-8)

Safety Data

• Hazardous Substances Data: 886979-78-8(Hazardous Substances Data)

Usage

Description

2-Pyrazinecarboxamide, N-[(1S)-2-[[(1R)-1-hydroperoxy-3-methylbutyl]amino]-2-oxo-1-(phenylmethyl)ethyl]is a complex organic compound with a unique molecular structure. It is characterized by the presence of a pyrazine carboxamide group, a chiral center with (1S)-configuration, and a hydroperoxy-3-methylbutyl group attached to an amino function. Additionally, it features a 2-oxo-1-(phenylmethyl)ethyl moiety, which contributes to its overall chemical properties and potential applications.

Uses

Used in Pharmaceutical Industry:
2-Pyrazinecarboxamide, N-[(1S)-2-[[(1R)-1-hydroperoxy-3-methylbutyl]amino]-2-oxo-1-(phenylmethyl)ethyl]is used as an impurity in the development and manufacturing process of Bortezomib (B675700). Bortezomib is the first proteasome inhibitor to be approved by the US FDA for the treatment of multiple myeloma, a type of blood cancer. The presence of this compound as an impurity is crucial for ensuring the quality, safety, and efficacy of Bortezomib as a therapeutic agent.
In the pharmaceutical industry, the control and monitoring of impurities, such as 2-Pyrazinecarboxamide, N-[(1S)-2-[[(1R)-1-hydroperoxy-3-methylbutyl]amino]-2-oxo-1-(phenylmethyl)ethyl]-, are essential for maintaining the integrity and effectiveness of drugs like Bortezomib. 2-PyrazinecarboxaMide, N-[(1S)-2-[[(1R)-1-hydroperoxy-3-Methylbutyl]aMino]-2-oxo-1-(phenylMethyl)ethyl]plays a significant role in the quality assurance processes and contributes to the overall safety and efficacy of the final drug product.